Prominent life sciences investor RA Capital Management has exited its entire position in Dianthus Therapeutics, a clinical-stage biotech firm. The fund sold all 2.61 million of its shares, which were previously valued at approximately $219.18 million. Before the sale, this holding represented a significant 2.32% of RA Capital's reported portfolio.
This trade was disclosed in a quarterly 13F filing with the SEC on August 14, 2026, which details the firm's holdings as of June 30, 2026. Dianthus Therapeutics focuses on developing antibody treatments for severe and rare autoimmune diseases. The filing reflects trading activity from the second quarter and not a real-time transaction.